ARTICLE | Financial News
Aduro closes $55 million C round
June 11, 2014 11:38 PM UTC
Aduro BioTech Inc. (Berkeley, Calif.) raised an undisclosed amount in a tranched $55 million series C round from new investor Johnson & Johnson Development Corporation (JJDC) and existing investor Morningside Group. Other undisclosed new and existing investors participated. JJDC is the venture arm of Johnson & Johnson (NYSE:JNJ). Aduro's lead internal program is CRS-207, a live attenuated strain of Listeria monocytogenes that expresses human mesothelin. The program is in the Phase IIb ECLIPSE trial to treat metastatic pancreatic cancer. ...